The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach

by Suryaprakash Raichur, Bodo Brunner, Maximilian Bielohuby, Gitte Hansen, Anja Pfenninger, Bing Wang, Jens C. Bruning, Philip Just Larsen, Norbert Tennagels
Published 2019-03-01

Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice

by Sebastian Brachs, Angelika F. Winkel, Hui Tang, Andreas L. Birkenfeld, Bodo Brunner, Kerstin Jahn-Hofmann, Daniel Margerie, Hartmut Ruetten, Dieter Schmoll, Joachim Spranger
Published 2016-11-01

Chronic Activation of Hepatic Nrf2 Has No Major Effect on Fatty Acid and Glucose Metabolism in Adult Mice.

by Sebastian Brachs, Angelika F Winkel, James Polack, Hui Tang, Maria Brachs, Daniel Margerie, Bodo Brunner, Kerstin Jahn-Hofmann, Hartmut Ruetten, Joachim Spranger, Dieter Schmoll
Published 2016-01-01

Correction: Chronic Activation of Hepatic Nrf2 Has No Major Effect on Fatty Acid and Glucose Metabolism in Adult Mice.

by Sebastian Brachs, Angelika F Winkel, James Polack, Hui Tang, Maria Brachs, Daniel Margerie, Bodo Brunner, Kerstin Jahn-Hofmann, Hartmut Ruetten, Joachim Spranger, Dieter Schmoll
Published 2017-01-01

Liver-Specific Knockdown of Class IIa HDACs Has Limited Efficacy on Glucose Metabolism but Entails Severe Organ Side Effects in Mice

by Nicole Ziegler, Suryaprakash Raichur, Bodo Brunner, Ulrike Hemmann, Manuela Stolte, Uwe Schwahn, Hans-Peter Prochnow, Christiane Metz-Weidmann, Norbert Tennagels, Daniel Margerie, Paulus Wohlfart, Maximilian Bielohuby
Published 2020-08-01